Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase I/II vemurafenib in unresectable or metastatic BRAF V600–mutant melanoma (Japan)
jRCT2080221895Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in melanoma, sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
vemurafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2080221895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221895.